These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21623581)

  • 1. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control.
    Massy ZA; Hénaut L; Larsson TE; Vervloet MG
    Semin Nephrol; 2014 Nov; 34(6):648-59. PubMed ID: 25498383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
    Quarles LD
    Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cinacalcet in hyperfunctioning parathyroid diseases.
    Imanishi Y; Inaba M; Kawata T; Nishizawa Y
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S7-S11. PubMed ID: 19765257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.
    Sumida K; Nakamura M; Ubara Y; Marui Y; Tanaka K; Takaichi K; Tomikawa S; Inoshita N; Ohashi K
    Am J Nephrol; 2013; 37(5):405-12. PubMed ID: 23594726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium-mediated parathyroid hormone release changes in patients treated with the calcimimetic agent cinacalcet.
    de Francisco AL; Izquierdo M; Cunningham J; Piñera C; Palomar R; Fresnedo GF; Amado JA; Unzueta MG; Arias M
    Nephrol Dial Transplant; 2008 Sep; 23(9):2895-901. PubMed ID: 18424820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet: will it play a role in reducing cardiovascular events?
    Karohl C; Raggi P
    Future Cardiol; 2012 May; 8(3):357-70. PubMed ID: 22420327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utilization of cinacalcet in hypercalcemic conditions.
    Messa P; Alfieri C; Brezzi B
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcimimetics].
    Messa P; Como G; Brezzi B
    G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcimimetics: physiology, results of preclinical and clinical studies, and perspectives].
    Torres PU
    Nephrol Ther; 2011 Apr; 7(2):99-104. PubMed ID: 21310676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.
    Nemeth EF; Shoback D
    Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
    Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
    Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Insight: renal indications of calcimimetics.
    Shahapuni I; Monge M; Oprisiu R; Mazouz H; Westeel PF; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):316-25. PubMed ID: 16932453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of evocalcet for unmet needs among calcimimetic agents.
    Hamano N; Endo Y; Kawata T; Fukagawa M
    Expert Rev Endocrinol Metab; 2020 Sep; 15(5):299-310. PubMed ID: 32552012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
    Torres PA; De Broe M
    Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cinacalcet - an allosteric enhancer at the Ca2+-receptor].
    Kebig A; Mohr K
    Dtsch Med Wochenschr; 2008 Aug; 133(33):1681-3. PubMed ID: 18661462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)].
    Nagano N; Kawata T; Wada M
    Nihon Yakurigaku Zasshi; 2008 Nov; 132(5):301-8. PubMed ID: 19008642
    [No Abstract]   [Full Text] [Related]  

  • 19. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
    Akizawa T; Ikejiri K; Kondo Y; Endo Y; Fukagawa M
    Ther Apher Dial; 2020 Jun; 24(3):248-257. PubMed ID: 31486206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent updates on the calcium-sensing receptor as a drug target.
    Trivedi R; Mithal A; Chattopadhyay N
    Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.